May 21, 2018
|
Realm Therapeutics Presents Data Highlighting its Proprietary Immunomodulatory Technology's Potential in Acne and Psoriasis at IID 2018
|
May 2, 2018
|
Realm Therapeutics Files Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares
|
April 26, 2018
|
Realm Therapeutics plc ("Realm Therapeutics", "Realm", or the "Company") Notice of Full Year 2017 Results
|
February 27, 2018
|
Realm Therapeutics Strengthens its Patent Portfolio with Two New USPTO Notice of Allowances
|
February 20, 2018
|
Realm Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
|
February 15, 2018
|
Realm Therapeutics Highlights Strong 2017 Performance and Outlines 2018 Milestones
|
January 2, 2018
|
Realm Therapeutics to Present at the 5th Annual Dermatology Summit
|
December 12, 2017
|
Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR013 for the Treatment of Allergic Conjunctivitis
|